CTLA4 and enterocolitis: demonstrated that long‐term treatment with an Fc‐effector anti‐CTLA4 antibody twice weekly in Balb/c mice induces enterocolitis, and C57BL/6 mice were less prone to developing Fc‐effector anti‐CTLA4‐mediated colitis compared with Balb/c mice, and monotherapy anti‐PD‐1 treatment didn't elicit gut inflammation.